v3.25.3

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 112,672	$ 74,293
Short-term investments	187,594	144,570
Prepaid expenses and other current assets	20,952	8,116
Total current assets	321,218	226,979
Long-term investments	5,108	47,683
Right of use assets - operating leases	49	154
Other assets	180	126
Total assets	326,555	274,942
Current liabilities:
Accounts payable	5,933	3,782
Accrued expenses	15,569	13,330
Operating lease liabilities	56	162
Total current liabilities	21,558	17,274
Operating lease liabilities, net of current amount		14
Total liabilities	21,558	17,288
Stockholders' equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding
Common stock $0.0001 par value, 200,000,000 shares authorized; 37,490,439 and 33,706,765 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	4	3
Additional paid-in capital	673,884	496,195
Accumulated deficit	(369,097)	(238,333)
Accumulated other comprehensive income (loss)	206	(211)
Total stockholders' equity	304,997	257,654
Total liabilities and stockholders' equity	$ 326,555	$ 274,942

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

ArriVent BioPharma, Inc. 10-Q